On Thursday, Shares of AbbVie Inc (NYSE:ABBV), gained 0.72% to $56.03. 6.74 million shares of the company were exchanged.
Full results from the Phase 3 DECIDE study published this week in the New England Journal of Medicine (NEJM), in addition to new post-hoc analyses of Phase 3 clinical data presented at an international congress, show once-monthly, investigational ZINBRYTA™ (daclizumab high-yield process [HYP]) improved results on key measures of multiple sclerosis (MS) disease activity in patients with relapsing-remitting MS (RRMS) contrast to interferon beta-1a 30 mcg intramuscular (IM) injection. In the new post-hoc analyses, ZINBRYTA was shown to enhance the percentage of patients achieving no evidence of clinical and MRI disease activity, improve cognitive processing speed and reduce 24-week confirmed disability progression across a broad range of subgroups at two years contrast to interferon beta-1a IM. Lead investigators on behalf of Biogen (BIIB) and AbbVie (ABBV) presented these new findings recently at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain (7-10 October).
Efficacy Contrast to Interferon Beta-1a IM
New post-hoc analyses of data from DECIDE presented at ECTRIMS assessed multiple measures of MS disease activity and showed that contrast to interferon beta-1a IM over two years (p values are nominal):
- More ZINBRYTA-treated patients exhibited no evidence of disease activity (NEDA) (24.6% as compared to 14.2%; p<0.0001; n=1,841). These results were based on a greater number of ZINBRYTA patients achieving both clinical NEDA (no relapses and no disability progression) and MRI NEDA (no new/newly enlarging T2-hyperintense lesions and no gadolinium-improved lesions).
- ZINBRYTA-treated patients showed improvement in cognitive processing speed and prevention of clinically meaningful cognitive decline, as measured by greater mean improvements from baseline on the Symbol Digit Modalities Test (SDMT; +4.08 [12.4] as compared to +2.89 [12.7]; p=0.0274). Higher percentages of ZINBRYTA patients had a ≥3-point (60.0% as compared to 54.1%; p=0.0153) or ≥4-point (55.4% as compared to 50.1%; p=0.0366) improvement in SDMT scores at week 96 (n=1,402).
- ZINBRYTA treatment resulted in reductions in the risk of 24-week confirmed disability progression across a wide range of pre-specified patient subgroups based on baseline characteristics.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Shares of KeyCorp (NYSE:KEY), inclined 0.23% to $13.34, during its last trading session.
In the last trading session, the stock moved on low volume, trading at a volume of 8.59 M as compared to its average daily volume of 10.03 million shares.
BNY Mellon, and KeyBank (KEY), declared that BNY Mellon’s Treasury Services business will provide private label trade processing services to KeyBank’s Global Trade Group.
The integration of BNY Mellon’s capabilities and experience with KeyBank’s leading global trade platform will leverage BNY Mellon’s trade processing resources and extensive document and transaction processing capabilities. Specific outsourcing services being offered to KeyBank comprise a Web-based letter of credit information delivery and document administration system; a Web-based trade letter of credit portal; and a Web-based system for documentary collections, document review, funds transfer and trade reporting. The range of services being offered by BNY Mellon integrates all of the essential components of letter of credit and documentary collection transactions into a single platform.
KeyCorp. operates as the bank holding company for KeyBank National Association that provides various retail and commercial banking services to individual, corporate, and institutional clients in the United States.
At the end of Thursday’s trade, Shares of Texas Instruments Incorporated (NASDAQ:TXN), inclined 0.94% to $51.52.
It traded in a range of $50.36 and $51.54, exchanging hands with 6.43 million shares.
Texas Instruments (TI) (TXN) declared its SimpleLink™ Wi-Fi® wireless microcontroller (MCU) easily and securely connects IoT endpoints to the Amazon Web Services (AWS) cloud for remote administration and data analysis. The AWS IoT Software Development Kit (SDK) is now accessible for TI’s low-power SimpleLink™ Wi-Fi® CC3200 wireless MCU LaunchPad™ kit, enabling developers to quickly establish a connection to AWS IoT services and right away start development on their IoT designs.
TI’s SimpleLink Wi-Fi CC3200 wireless MCU LaunchPad is an evaluation kit for the industry’s first single-chip, low-power Wi-Fi solution with a built-in programmable MCU. The CC3200 LaunchPad comprises a temperature sensor and an accelerometer, but through add-on BoosterPack™ plug-in boards, it enables easy integration of additional sensors to assist developers prototype their IoT applications. Developers can now leverage the SDK to store and analyze sensor data, trigger actions and interact with their cloud-connected designs and products from mobile and web applications.
Semiconductor innovations are at the foundation of the IoT connecting people, things and cloud. TI innovations are enabling the IoT by expanding from wired connections to wireless connectivity, driving down power to enable battery-operated connected products. Additionally, TI is making development easier by providing certified modules and pre-integrated cloud connectivity software stacks.
Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. It operates through two segments, Analog and Embedded Processing.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
